MedTrace Logo

Study on Cerebral Protection of Dexmedetomidine for Patients With Traumatic Brain Injury

NCT04006054 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2019-07-02

No results posted yet for this study

Summary

The aim of the study is to investigate whether dexmedetomidine could suppress catecholamine release into peripheral blood to prevent PSH attacks and to achieve neuroprotection.

Conditions

Interventions

DRUG

Dexmedetomidine

When the patients who suffered traumatic brain injury are in NICU，Dexmedetomidine is given for sedation about 5 days .

DRUG

Midazolam

When the patients who suffered traumatic brain injury are in NICU，Midazolam is given for sedation about 5 days .

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-06
Primary Completion
2021-06-30
Completion
2021-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04006054 on ClinicalTrials.gov